The Details:
"The recent authorization by the FDA to commence our pivotal clinical study, following submission of the results of our extensive pre-clinical studies and tests, reinforces our confidence in our innovative technology,” commented Harel Gadot, CEO of Microbot Medical.
“It is also a testament to our commitment to meet meaningful milestones as we continue our path towards potential regulatory clearance and subsequent commercialization in the US and other regions across the globe."
Microbot shares are moving on heavy trading volume following the company's announcement. According to data from Benzinga Pro, more than 74.7 million shares have already been traded in the session, far exceeding the stock’s 100-day average of less than 96,000 shares.
Related News: What’s Going On With Snowflake Stock?
How To Buy MBOT Stock:
By now you're likely curious about how to participate in the market for Microbot Medical – be it to purchase shares, or even attempt to bet against the company.
In the the case of Microbot Medical, which is trading at $1.94 as of publishing time, $100 would buy you 51.55 shares of stock.
MBOT Price Action: According to Benzinga Pro, Microbot shares are up 88% at $1.88 at the time of publication Monday.
Image: PublicDomainPictures from Pixabay
© 2026 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.
To add Benzinga News as your preferred source on Google, click here.
